A Message from our Founder on International Clinical Trials Day

At MMS, we take great pride in our work as a data CRO and hence May 20th has a special significance for us as International Clinical Trials Day.

Clinical trials are the backbone of drug development and allow our industry to look at the efficacy and safety of medications in an unbiased manner. The entire pharmaceutical industry is deeply indebted to patients who participate in clinical trials and allow us to provide the data for various therapies on the market. This day is the basis for many life-saving therapies, including the recent COVID vaccines, without which all of mankind would have had a major setback.

Our core services at MMS and our values to improve patient lives align with this day. As a quality-focused data CRO and a pioneer in data transparency, every colleague at MMS recognizes and appreciates clinical trial data as the foundation of our work and strives hard to make this meaningful from a clinical and regulatory perspective. Whether we are creating a dataset, writing a study report or submission, anonymizing data or reports, or auditing clinical trial sites, we strive to honor those patients contributing to the clinical trial pool with our diligence and efforts.

Today, on International Clinical Trials Day, we pause, reflect and are grateful to have an opportunity to support patients across a spectrum of therapeutic areas, including rare diseases, to the best of our abilities and serve humanity in our own little way. We also celebrate all MMS colleagues who directly and indirectly support clinical trials and patients worldwide. Take a moment today to reflect and celebrate your effort and personal mission to this important work.

Dr. Uma Sharma is the founder and Chief Scientific Officer at MMS.

To learn more about MMS services, visit our website

Suggested For You

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

perspectives

July 16th, 2024

Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives

July 9th, 2024

Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives

July 2nd, 2024

Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology

perspectives

June 21st, 2024

Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry

perspectives

June 14th, 2024

A Structured Approach to Benefit-Risk Assessment Throughout Product Development in the Pharmaceutical Industry

perspectives

June 6th, 2024

Datacise and Diversity in Patient Enrollment: Combining Geospatial and Demographic Data to Aid Site Selection

perspectives

May 29th, 2024

Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules

perspectives

May 21st, 2024

Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of “Nonmedical Use” On Labelling

perspectives

May 10th, 2024

Psychedelics in Drug Development and Regulatory Considerations Part I: Benefit-Risk

perspectives

April 29th, 2024

Validation of Clinical Dashboards for Decision Making